CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 27, 2026, STAT News reported that: “The Food and Drug Administration said Monday that Capricor Therapeutics’ stem cell treatment for Duchenne muscular dystrophy did not meet the objectives of a Phase 3 trial — contrary to the company’s claims last year.” Following this news, the price of the Company’s stock dropped. If you purchased Capricor stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected] or Joshua Karr, Esq. at [email protected] , call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/capricor/ to discuss your legal rights.